This trial will compare a new immunotherapy drug to the current standard of care for treating a certain type of blood cancer.
- Diffuse Large B Cell Lymphoma (DLBCL)
1 Primary · 18 Secondary · Reporting Duration: Up to 4 years
3 Treatment Groups
Part 2: Standard Immunochemotherapy (R-GemOx)
1 of 3
Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 3
Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)
1 of 3
350 Total Participants · 3 Treatment Groups
Primary Treatment: Loncastuximab Tesirine · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the status of Loncastuximab Tesirine's FDA approval?
"This clinical trial is a Phase 3, meaning that while there is data supporting efficacy, there is also multiple rounds of data supporting safety. Therefore, our team has given Loncastuximab Tesirine a safety score of 3." - Anonymous Online Contributor
What indications is Loncastuximab Tesirine commonly used to treat?
"Loncastuximab Tesirine is most commonly used to treat diffuse large b-cell lymphoma (dlbcl), but can also be used as part of the treatment plan for small cell lung cancer (sclc), head and neck carcinoma, and cervical cancers." - Anonymous Online Contributor
Are there still positions open for participants in this trial?
"This research study is currently recruiting patients, as indicated by the listing on clinicaltrials.gov. This trial was first announced on September 16th, 2020 with the last update on October 26th, 2020." - Anonymous Online Contributor
At how many locations is this experiment being conducted?
"To minimise the burden of travel on participants, the 17 clinical trial sites are located in La Jolla, Redlands, and Montréal as well as 14 other cities." - Anonymous Online Contributor
What is the background of Loncastuximab Tesirine in medical research?
"At present, there are 1164 concurrent clinical trials for Loncastuximab Tesirine globally, with the majority of these (336) being in Phase 3. The vast majority of these clinical trials are located in Guangzhou, Guangdong; however, there are 51462 total locations running studies for Loncastuximab Tesirine." - Anonymous Online Contributor